48-week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs. continuing on AZT/3TC: 48-week interim analysis of the RECOMB trialEsteban Ribera, ML Álvarez, Estebán Martínez et al.|Journal of the International AIDS Society|2008Cited by 2